当前位置:
X-MOL 学术
›
Cancer Genet.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC
Cancer Genetics ( IF 1.9 ) Pub Date : 2023-12-10 , DOI: 10.1016/j.cancergen.2023.12.001 Teppei Yamaguchi , Katsuhiro Masago , Eiichi Sasaki , Hiroaki Kuroda , Hirokazu Matsushita , Yoshitsugu Horio
Cancer Genetics ( IF 1.9 ) Pub Date : 2023-12-10 , DOI: 10.1016/j.cancergen.2023.12.001 Teppei Yamaguchi , Katsuhiro Masago , Eiichi Sasaki , Hiroaki Kuroda , Hirokazu Matsushita , Yoshitsugu Horio
Abstract not available
中文翻译:
EML4-ALK 变体 3a/b 作为 EGFR L858R 阳性 NSCLC 患者奥希替尼耐药的机制
摘要不可用
更新日期:2023-12-10
中文翻译:
EML4-ALK 变体 3a/b 作为 EGFR L858R 阳性 NSCLC 患者奥希替尼耐药的机制
摘要不可用